[go: up one dir, main page]

GT201400301A - 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 - Google Patents

7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2

Info

Publication number
GT201400301A
GT201400301A GT201400301A GT201400301A GT201400301A GT 201400301 A GT201400301 A GT 201400301A GT 201400301 A GT201400301 A GT 201400301A GT 201400301 A GT201400301 A GT 201400301A GT 201400301 A GT201400301 A GT 201400301A
Authority
GT
Guatemala
Prior art keywords
pirrolo
lrrk2
disease
aminho
pyrimidins
Prior art date
Application number
GT201400301A
Other languages
English (en)
Inventor
Galatsis Paul
Kormos Bethany Lyn
Verhoest Patrick Robert
Travis T Wager
Zhang Lei
Hayward Matthew Merrill
Herderson Jaclyn
Ravi G Kurumbail
Stepan Antonia Friederike
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49029142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400301(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of GT201400301A publication Critical patent/GT201400301A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA NUEVOS 4,5-DISUSTITUIDO-7H-PIRROLO [2,3-D] PIRIMIDINA DE FÓRMULA I, Y LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN EL QUE R1, R2, R3, R4 Y R5 SON COMO SE DEFINEN EN LA ESPECIFICACIÓN.LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE FÓRMULA I Y AL USO DE LOS COMPUESTOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON LRRK2, TALES COMO LAS ENFERMEDADES NEURODEGENERATIVAS INCLUYENDO LA ENFERMEDAD DE PARKINSON O LA ENFERMEDAD DE ALZHEIMER, CÁNCER, ENFERMEDAD DE CROHN O LA LEPRA.
GT201400301A 2012-06-29 2014-12-29 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 GT201400301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666299P 2012-06-29 2012-06-29
US201361820828P 2013-05-08 2013-05-08

Publications (1)

Publication Number Publication Date
GT201400301A true GT201400301A (es) 2015-06-02

Family

ID=49029142

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400301A GT201400301A (es) 2012-06-29 2014-12-29 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2

Country Status (32)

Country Link
US (2) US9156845B2 (es)
EP (2) EP2867236B1 (es)
JP (3) JP6189948B2 (es)
KR (1) KR20150027267A (es)
CN (2) CN104395315B (es)
AP (1) AP3902A (es)
AR (1) AR091628A1 (es)
AU (1) AU2013282869B2 (es)
BR (1) BR112014032913A2 (es)
CA (1) CA2878054C (es)
CL (1) CL2014003566A1 (es)
CO (1) CO7160063A2 (es)
CR (1) CR20140566A (es)
DO (1) DOP2014000303A (es)
EA (1) EA025186B1 (es)
ES (1) ES2637245T3 (es)
GE (1) GEP201706620B (es)
GT (1) GT201400301A (es)
HK (1) HK1204619A1 (es)
IL (1) IL236294A (es)
MD (1) MD20140130A2 (es)
MX (1) MX2014015769A (es)
NI (1) NI201400151A (es)
NZ (1) NZ702571A (es)
PE (1) PE20150153A1 (es)
PH (1) PH12014502886A1 (es)
SG (1) SG11201408044QA (es)
TN (1) TN2014000537A1 (es)
TW (1) TWI482774B (es)
UY (1) UY34883A (es)
WO (1) WO2014001973A1 (es)
ZA (1) ZA201409136B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2617339T3 (es) 2010-12-16 2017-06-16 Calchan Limited Derivados de pirrolopirimidina inhibidores de ASK1
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
KR20150027267A (ko) * 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
US8963597B1 (en) * 2013-10-02 2015-02-24 Nanya Technology Corporation Cross-domain enablement method and electronic apparatus
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
AU2015210593A1 (en) * 2014-01-29 2016-07-07 Glaxosmithkline Intellectual Property Development Limited Compounds
CA2937430A1 (en) * 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
US10058559B2 (en) 2014-05-15 2018-08-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Treatment or prevention of an intestinal disease or disorder
CN104086553B (zh) * 2014-06-13 2016-04-27 南京药石科技股份有限公司 一种制备7-溴咪唑并[2,1-f][1,2,4]三嗪-4-胺的方法
US10004751B2 (en) 2014-07-10 2018-06-26 The J. David Gladstone Institutes Compositions and methods for treating Dengue virus infection
AU2015345054B2 (en) 2014-11-14 2020-03-05 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
FR3041640B1 (fr) * 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
JP7101176B2 (ja) * 2017-02-03 2022-07-14 レオ ファーマ アクティーゼルスカブ 新規ＪＡＫキナーゼ阻害剤としての５－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）－５－アザスピロ［２．５］オクタン－８－カルボン酸誘導体
CN106831790B (zh) * 2017-02-17 2019-07-26 四川大学华西医院 7H-吡咯并[2,3-d]嘧啶衍生物
JP6728503B2 (ja) 2017-02-24 2020-07-22 テグ−キョンプク メディカル イノベーション ファウンデーション 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物
KR20190131981A (ko) * 2018-05-18 2019-11-27 재단법인 대구경북첨단의료산업진흥재단 외상성 뇌손상 또는 뇌졸중의 예방 또는 치료용 약학적 조성물
KR101990739B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR20200023231A (ko) * 2018-08-23 2020-03-04 재단법인 대구경북첨단의료산업진흥재단 Lrrk 키나아제 저해제를 유효성분으로 함유하는 피리미딘 유도체의 신규 용도
KR101992059B1 (ko) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
SG11202112362YA (en) 2019-05-08 2021-12-30 Vimalan Biosciences Inc Jak inhibitors
KR20220051351A (ko) 2019-08-08 2022-04-26 비말란 바이오사이언스즈, 인크. Jak 억제제
WO2021062036A1 (en) * 2019-09-25 2021-04-01 Vimalan Biosciences, Inc. Jak inhibitors
KR20230012464A (ko) * 2020-02-25 2023-01-26 브이아이비 브이지더블유 류신-풍부 반복 키나제 2 알로스테릭 조절제
CN111671757A (zh) * 2020-07-16 2020-09-18 福建医科大学附属协和医院 3-[4-（4-吗啉基）-7h-吡咯并[2,3-d]嘧啶-5-基]苯甲腈制药用途
IL300024A (en) * 2020-10-20 2023-03-01 Hoffmann La Roche Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
US20230392206A1 (en) * 2020-10-26 2023-12-07 Neuron23, Inc. Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2
IL308184A (en) * 2021-05-05 2024-01-01 Kare Chemical Tech Inc Processes for the preparation of catalytic tryptamines and starting materials
WO2023039368A1 (en) * 2021-09-07 2023-03-16 Ptc Therapeutics, Inc. Methods for treating neurogenerative diseases
US20250051337A1 (en) * 2021-09-28 2025-02-13 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of serine/threonine protein kinase stk3 or stk4 and uses thereof
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
JP2024541934A (ja) 2021-10-27 2024-11-13 ハー・ルンドベック・アクチエゼルスカベット Ｌｒｒｋ２阻害剤
US11958865B1 (en) 2022-09-15 2024-04-16 H. Lundbeck A/S Leucine-rich repeat kinase 2 (LRRK2) inhibitors
WO2025019585A1 (en) * 2023-07-17 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Kinase inhibitors

Family Cites Families (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
JP2890448B2 (ja) 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5658889A (en) 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US4994468A (en) 1989-03-07 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinolone derivatives
US5795977A (en) 1989-09-15 1998-08-18 Metabasis Therapeutics, Inc. Water soluble adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5763597A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5646128A (en) 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
JPH03271289A (ja) 1990-03-16 1991-12-03 Nissan Chem Ind Ltd ピラゾロピリジン誘導体の製造法及びジヒドロピラゾロピリジン誘導体
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JP3130342B2 (ja) 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
JP3271289B2 (ja) 1992-02-28 2002-04-02 スズキ株式会社 ４サイクルエンジンのバルブ駆動装置
EP0633886B1 (en) 1992-04-03 2000-10-18 PHARMACIA & UPJOHN COMPANY Pharmaceutically active bicyclic-heterocyclic amines
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
WO1995011898A1 (en) 1992-05-12 1995-05-04 Nissan Chemical Industries Ltd. Condensed pyridine type mevalonolactone intermediate and process for its production
JPH05310700A (ja) 1992-05-12 1993-11-22 Sagami Chem Res Center 縮合ピリジン系メバロノラクトン中間体及びその製法
JPH0641114A (ja) 1992-05-25 1994-02-15 Nissan Chem Ind Ltd 新規メバロノラクトン類とその製法
JPH06116239A (ja) 1992-10-05 1994-04-26 Nissan Chem Ind Ltd ７−置換−３，５−ジヒドロキシヘプタ−６−イン酸類
AU5161193A (en) 1992-10-16 1994-05-09 Nippon Soda Co., Ltd. Pyrimidine derivative
DE69432629T3 (de) 1993-01-25 2008-01-17 Takeda Pharmaceutical Co. Ltd. Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
DE4304455A1 (de) 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
JP3350739B2 (ja) 1993-06-10 2002-11-25 コニカ株式会社 黒白ハロゲン化銀写真感光材料の現像処理方法
CN1102644A (zh) 1993-11-11 1995-05-17 财团法人相模中央化学研究所 缩合吡啶型甲羟戊酸内酯中间体及其制备方法
JPH07281365A (ja) 1994-04-07 1995-10-27 Konica Corp 写真感光材料の処理方法
DK0682027T3 (da) 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
JP3448724B2 (ja) 1995-11-29 2003-09-22 コニカ株式会社 ハロゲン化銀写真感光材料用現像剤及びその処理方法
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
BR9709443B1 (pt) * 1996-03-15 2009-05-05 n-7-heterociclil-pirrol[2,3-d]pirimidinas, bem como composições farmacêuticas compreendendo as mesmas.
JPH10213887A (ja) 1996-11-26 1998-08-11 Konica Corp 黒白ハロゲン化銀写真感光材料の処理方法
EP0946554A1 (en) * 1996-11-27 1999-10-06 Pfizer Inc. Fused bicyclic pyrimidine derivatives
EP0846981A1 (en) 1996-12-03 1998-06-10 Konica Corporation Method for processing black-and-white silver halide photographic light-sensitive material
JP3543249B2 (ja) 1996-12-18 2004-07-14 コニカミノルタホールディングス株式会社 黒白ハロゲン化銀写真感光材料の処理方法
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6929808B2 (en) 2000-11-03 2005-08-16 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
EP1087970B1 (en) 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6309811B2 (en) 1999-07-21 2001-10-30 Eastman Kodak Company Color photographic element containing nitrogen heterocycle derivative and inhibitor releasing coupler
SK288711B6 (sk) 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
AU2001264313A1 (en) 2000-06-20 2002-01-02 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
KR20030062442A (ko) 2000-12-22 2003-07-25 와이어쓰 5-하이드록시트립타민-6-리간드로서의 헤테로사이클인다졸및 아자인다졸 화합물
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
US20030114467A1 (en) * 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Ａβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
WO2003076658A2 (en) 2002-03-08 2003-09-18 Decode Genetics Ehf. A susceptibility gene for late-onset idiopathic parkinson's disease
EP1545515A1 (en) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
AU2003279216A1 (en) 2002-10-09 2004-05-04 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
DE10259382A1 (de) 2002-12-18 2004-07-01 Abbott Gmbh & Co. Kg 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-4-on-Derivate, ihre Herstellung und Verwendung
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
DK1696920T3 (en) 2003-12-19 2015-01-19 Plexxikon Inc RELATIONS AND PROCEDURES FOR THE DEVELOPMENT OF LAW MODULATORS
US20050187389A1 (en) * 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
DK1735278T3 (da) 2004-04-01 2010-04-12 Lilly Co Eli Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser
EP1756108A2 (en) 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
GEP20094723B (en) 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
CA2570043A1 (en) 2004-06-08 2005-12-22 Chiron Corporation Env polypeptide complexes and methods of use
AU2005260032A1 (en) 2004-06-29 2006-01-12 Amgen Inc. Pyrrolo[2,3-d]pyrimidines that modulate ACK1 and LCK activity
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
WO2006045392A2 (en) 2004-10-21 2006-05-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
EP1851220A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
EP1899296B1 (en) 2005-06-22 2010-11-17 Pfizer Products Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
EP1968568A4 (en) 2005-12-22 2011-04-13 Glaxosmithkline Llc HEMMER OF NUTS ACTIVITY
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
JP2009539762A (ja) 2006-03-13 2009-11-19 ファイザー・プロダクツ・インク Ｈ３受容体のテトラリン拮抗薬
CN101426927B (zh) 2006-03-14 2012-05-23 塞尔卓姆股份公司 鉴定lrrk2相互作用分子和纯化lrrk2的方法
WO2007124096A2 (en) 2006-04-21 2007-11-01 The Trustees Of Columbia University In The City Of New York Lrrk2 regulaton of neuronal process morphology
GB0610317D0 (en) 2006-05-24 2006-07-05 Medical Res Council Antiparasitic compounds and compositions
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
BRPI0713738A2 (pt) * 2006-06-20 2014-06-24 Novartis Ag Biomarcadores para a progressão de doença alzheimer
US8466163B2 (en) 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
WO2008075007A1 (en) * 2006-12-21 2008-06-26 Cancer Research Technology Limited Morpholino-substituted bicycloheteroaryl compounds and their use as anti cancer agents
WO2008091799A2 (en) 2007-01-22 2008-07-31 The Trustees Of Columbia University In The City Of New York Cell-based methods for identifying inhibitors of parkinson's disease-associated lrrk2 mutants
CN101631545B (zh) 2007-01-22 2013-03-13 辉瑞产品公司 治疗性化合物的甲苯磺酸盐及其药物组合物
FR2912744B1 (fr) 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
GB0706709D0 (en) 2007-04-05 2007-05-16 Medical Res Council Methods
CA2682733A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors
MY147330A (en) 2007-05-11 2012-11-30 Pfizer Amino-heterocyclic compounds
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2009000319A1 (de) 2007-06-22 2008-12-31 Schulz Hans M Handeingabegerät
WO2009005730A1 (en) 2007-06-27 2009-01-08 Cornell University Transgenic animal models of parkinson's disease
WO2009030270A1 (en) 2007-09-03 2009-03-12 Novartis Ag Dihydroindole derivatives useful in parkinson's disease
US8288383B2 (en) 2007-09-14 2012-10-16 Sanofi 3-methyl-2- ( (2S) -2- (4- (3-methyl-L, 2, 4-oxadiazol-5-YL) phenyl) morpholino) -6- (pyrim-idin-4-yl) pyrimidin-4 (3H) -one as tau protein kinase inhibitor
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
JP5576290B2 (ja) 2007-12-05 2014-08-20 ヨハネス、グーテンベルク−ウニフェルジテート、マインツ 白血病の管理における３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド誘導体の用途
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
KR101667822B1 (ko) 2008-04-30 2016-10-19 내셔날 헬스 리서치 인스티튜트 오로라 키나아제 저해제용 접합 2고리 피리미딘 화합물
DE102008025751A1 (de) 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
DE102008031517A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
EP2320895A2 (en) 2008-07-03 2011-05-18 Exelixis, Inc. Cdk modulators
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
FR2935712A1 (fr) 2008-09-05 2010-03-12 Ct Hospitalier Regional Univer Methode de detection de l'expression differentielle d'un ensemble de marqueurs moleculaires associee a la maladie de parkinson
GB2463656B (en) 2008-09-18 2010-10-13 Medical Res Council Substrate of LRRK2 and methods of assessing LRRK2 activity
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
US20100175140A1 (en) 2008-12-19 2010-07-08 The Johns Hopkins University Leucine-rich repeat kinase (LRRK2) drosophila model for parkinson's disease: wildtype1 (WT1) and G2019S mutant flies
US9266890B2 (en) 2009-01-06 2016-02-23 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders
EP2210887A1 (en) 2009-01-14 2010-07-28 Isdin, S.A. Bis resorcinyl triazine derivatives as protecting agents against UV radiation
WO2010085799A2 (en) 2009-01-26 2010-07-29 Tautatis, Inc. Compositions and method for the treatment of parkinson's disease
WO2010093191A2 (en) 2009-02-13 2010-08-19 Lg Life Sciences Ltd. Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
MX2011009807A (es) * 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
KR20100116765A (ko) 2009-04-23 2010-11-02 인제대학교 산학협력단 파킨슨병 치료제 스크리닝 방법
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
ES2659725T3 (es) 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
MX2012003778A (es) 2009-09-29 2012-06-01 Glaxo Group Ltd Compuestos novedosos.
FR2951172B1 (fr) 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
NZ630860A (en) 2009-10-29 2016-03-31 Genosco Bissubstituted pyrido[4,3-d]-pyrimindin-5-one kinase nhibitors and medical uses
KR20110049217A (ko) 2009-11-04 2011-05-12 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
US20150018301A1 (en) * 2009-11-06 2015-01-15 The Johns Hopkins University LRRK-2-Mediated Neuronal Toxicity
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
BR112012018413A2 (pt) 2009-12-21 2016-08-09 Samumed Llc 1h-pirazol[3,4-b]piridinas e usos terapêuticos dos mesmos.
WO2011106168A1 (en) 2010-02-24 2011-09-01 Dcam Pharma Inc Purine compounds for treating autoimmune and demyelinating diseases
US8367349B2 (en) 2010-04-19 2013-02-05 Medical Research Council Methods for identifying modulators of LRRK2
WO2011137022A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
US8895581B2 (en) 2010-05-17 2014-11-25 Boehringer Ingelheim International Gmbh 1H-imidazo[4,5-c]quinolines
WO2011149827A1 (en) 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
US9303322B2 (en) 2010-05-24 2016-04-05 Integran Technologies Inc. Metallic articles with hydrophobic surfaces
CN103038230B (zh) 2010-06-04 2016-05-25 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
KR101208198B1 (ko) 2010-08-27 2012-12-04 인제대학교 산학협력단 Ｌｒｒｋ２ 인산화효소 억제 활성을 갖는 화합물을 유효성분으로 함유하는 파킨슨병 치료 또는 예방용 약학조성물
WO2012028629A1 (en) 2010-09-02 2012-03-08 Glaxo Group Limited 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors
MX2013002784A (es) 2010-09-16 2013-04-24 Hutchison Medipharma Ltd Heteroarilos fusionados y sus usos.
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
JP5310700B2 (ja) 2010-10-27 2013-10-09 パナソニック株式会社 Ｌｅｄパッケージ製造システムおよびｌｅｄパッケージ製造システムにおける樹脂塗布方法
WO2012058193A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Leucine-rich repeat kinase enzyme activity
RS59106B1 (sr) 2010-11-10 2019-09-30 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
CN103348243A (zh) 2010-11-30 2013-10-09 基因泰克公司 Lrrk2的分析方法和生物标记物
EP2680695A4 (en) 2011-02-28 2014-09-10 Merck Sharp & Dohme COMPOUNDS FOR INHIBITING THE REPEATING ACTIVITY OF A LEUKINARY KINASEENZYME
US9493452B2 (en) 2011-03-24 2016-11-15 Southern Methodist University Compounds and derivatives of 2H-pyrido (3,2-b)(1, 4) oxazin 3)4H)-ones as raf kinase and LRRK2 inhibitors
GB201105137D0 (en) 2011-03-28 2011-05-11 Isis Innovation Therapeutic molecules for use in the suppression of Parkinson's disease
US8791112B2 (en) 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
JP6278406B2 (ja) 2011-04-21 2018-02-14 オリゲニス ゲーエムベーハーＯｒｉｇｅｎｉｓ Ｇｍｂｈ キナーゼ・インヒビターとしての複素環化合物
WO2012143144A1 (en) 2011-04-21 2012-10-26 Origenis Gmbh Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
US9187567B2 (en) 2011-05-18 2015-11-17 Parkinson's Institute Assay to determine LRRK2 activity in parkinson's disease
CA2837199A1 (en) 2011-05-23 2012-11-29 Elan Pharmaceuticals, Inc. Cinnoline compounds as inhibitor of lrrk2 kinase activity
US20140205537A1 (en) 2011-06-24 2014-07-24 Zenobia Therapeutics, Inc. Lrrk2 inhibitors
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
UA113186C2 (xx) 2011-09-30 2016-12-26 Макроциклічні інгібітори lrrk2 кінази
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
US9187484B2 (en) 2012-05-02 2015-11-17 Southern Research Institute Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
CN104271569B (zh) 2012-05-03 2016-08-24 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的吡唑氨基嘧啶衍生物
KR20150027267A (ko) 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
WO2014060113A1 (en) 2012-10-19 2014-04-24 Origenis Gmbh Novel kinase inhibitors
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP6116239B2 (ja) 2012-12-28 2017-04-19 キヤノン株式会社 被検体情報取得装置および被検体情報取得方法
EP2816840B1 (en) 2013-03-21 2017-01-04 Huawei Device Co., Ltd. Adaptive transmission scheme with two modes of operation
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN106413623B (zh) 2014-03-21 2020-07-03 阿莱恩技术有限公司 具有弹性体的分段的正畸矫正器

Also Published As

Publication number Publication date
GEP201706620B (en) 2017-02-10
SG11201408044QA (en) 2015-01-29
WO2014001973A1 (en) 2014-01-03
TN2014000537A1 (fr) 2016-03-30
JP2019073522A (ja) 2019-05-16
ES2637245T3 (es) 2017-10-11
CN105732639A (zh) 2016-07-06
DOP2014000303A (es) 2015-03-15
MX2014015769A (es) 2015-04-10
CL2014003566A1 (es) 2015-04-10
PH12014502886B1 (en) 2015-02-23
AP3902A (en) 2016-11-17
CR20140566A (es) 2015-01-09
CN104395315A (zh) 2015-03-04
MD20140130A2 (ro) 2015-04-30
PH12014502886A1 (en) 2015-02-23
CA2878054C (en) 2018-09-11
US9156845B2 (en) 2015-10-13
US20150366874A1 (en) 2015-12-24
KR20150027267A (ko) 2015-03-11
ZA201409136B (en) 2016-08-31
EP2867236B1 (en) 2017-06-14
AU2013282869B2 (en) 2015-12-24
BR112014032913A2 (pt) 2017-06-27
JP2017226684A (ja) 2017-12-28
HK1204619A1 (en) 2015-11-27
TW201414736A (zh) 2014-04-16
CO7160063A2 (es) 2015-01-15
JP2015522002A (ja) 2015-08-03
JP6462795B2 (ja) 2019-01-30
TWI482774B (zh) 2015-05-01
EA201492125A1 (ru) 2015-06-30
PE20150153A1 (es) 2015-02-05
NZ702571A (en) 2017-02-24
US20140005183A1 (en) 2014-01-02
IL236294A (en) 2016-09-29
AP2014008147A0 (en) 2014-12-31
JP6189948B2 (ja) 2017-08-30
NI201400151A (es) 2015-06-05
CA2878054A1 (en) 2014-01-03
CN104395315B (zh) 2016-08-17
UY34883A (es) 2014-01-31
EA025186B1 (ru) 2016-11-30
US9642855B2 (en) 2017-05-09
EP2867236A1 (en) 2015-05-06
EP3255049A1 (en) 2017-12-13
AU2013282869A1 (en) 2015-01-15
IL236294A0 (en) 2015-02-26
AR091628A1 (es) 2015-02-18

Similar Documents

Publication Publication Date Title
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
NI201400108A (es) Compuestos de heterociclilo
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
NZ705040A (en) Fused pyrimidines as inhibitors of p97 complex
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
MX2018003215A (es) Derivados de imidazo[4,5-c]quinolina e imidazo[4,5-c][1,5]naftirid ina novedosos como inhibidores de lrrk2.
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
CR20140399A (es) Pirrolidina-2-carboxamidas sustituidas
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
CO7131375A2 (es) Uracilos sustituidos bicíclicamente y uso de los mismos
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
IN2015DN01119A (es)
DOP2015000076A (es) Benzamidas
GB201209587D0 (en) Therapeutic compounds
CL2015003196A1 (es) Derivados de pirrolo[2,3-d]pirimidina como agonistas del receptor cb2.
CR20130318A (es) Nuevos compuestos de benzodioxol-piperazina
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
BR112017003651A2 (pt) derivados de isoquinolinona úteis no tratamento de câncer
CR20150092A (es) Derivados de diazepinona útiles para el tratamiento del síndrome x frágil, enfermedad de parkinson o enfermedad del reflujo
CO2017000211A2 (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas